Retireful LLC Takes Position in Organon & Co. (NYSE:OGN)

Retireful LLC bought a new position in shares of Organon & Co. (NYSE:OGN) in the fourth quarter, HoldingsChannel reports. The firm bought 12,529 shares of the company’s stock, valued at approximately $187,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OGN. Prospera Private Wealth LLC purchased a new position in Organon & Co. during the 3rd quarter valued at approximately $25,000. Horizon Bancorp Inc. IN raised its holdings in shares of Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after acquiring an additional 1,585 shares in the last quarter. William B. Walkup & Associates Inc. bought a new position in shares of Organon & Co. during the 2nd quarter valued at approximately $31,000. Versant Capital Management Inc grew its holdings in shares of Organon & Co. by 92.2% in the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after purchasing an additional 1,324 shares in the last quarter. Finally, Abich Financial Wealth Management LLC increased its position in Organon & Co. by 5,646.3% in the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after purchasing an additional 2,315 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Organon & Co. stock opened at $15.77 on Friday. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm’s fifty day moving average is $15.32 and its 200 day moving average is $18.24. The company has a market cap of $4.06 billion, a price-to-earnings ratio of 3.13, a PEG ratio of 0.86 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the prior year, the company posted $0.78 earnings per share. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. Sell-side analysts forecast that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.10%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.